Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- “Huge Seller” Re-Pricing Dominates Discussions at LDP Study Group
March 10, 2016
- 76 Products Join Japanese Pharmacopoeia: MHLW
March 10, 2016
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- PMDA Aims to Complete Reviews for 70% of Priority Products within 9 Months in FY2016
March 9, 2016
- MHLW Sorts Out Schemes for Humanitarian Trials, Patient-Initiated Mixed Care
March 8, 2016
- 77.8% of Generics Converge into Single Price Brand in FY2016 Revision: MHLW
March 7, 2016
- Drug Damage Watchdog Says NOAC Makers Paid Big for People Involved in AF Guidelines
March 7, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for February
March 4, 2016
- MHLW Panel Sets Official Price of Raw Plasma for Coagulation Factor Products at 11,100 Yen per Liter
March 4, 2016
- 439 APIs/1,057 Long-Listed Products Subject to Z2 Price Cut Rule in FY2016 Revisions
March 4, 2016
- AMED Selects 8 Projects for Pre-Orphan Designation System, 3 from Nobelpharma
March 4, 2016
- 416 APIs Eligible for Price Maintenance Scheme in FY2016 Revision; Astellas Only Japanese in Top 10 Premium Winner List
March 4, 2016
- Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
March 4, 2016
- MHLW to Revise Label Format, Possibly Scrap “Relative Contraindications” and “Careful Administration” Sections
March 3, 2016
- Show Us Your True Self during Surprise Manufacturing Inspections: PMDA Official
March 3, 2016
- FY2016 NHI Pricing Reform to Bring “1 Victory, 1 Defeat, 1 Draw” for Industry: MHLW Official
March 3, 2016
- MHLW Official Calls for Surprise Checks during Notified Inspections
March 2, 2016
- MHLW OKs 38 New APIs in 2015
March 2, 2016
- MHLW’s Onishi Urges Pref. Officials to Prep for Drug Price Survey toward 2017 Revision
March 2, 2016
- Japan Generic Use Rate at 59.7% in October 2015: MHLW
March 2, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…